Kenvue Inc. (NYSE:KVUE) Given Consensus Rating of “Hold” by Brokerages

Kenvue Inc. (NYSE:KVUE) has been given an average rating of “Hold” by the twelve research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $22.64.

A number of equities research analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Piper Sandler boosted their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th.

Kenvue Trading Down 0.1 %

Shares of Kenvue stock opened at $24.10 on Friday. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $46.20 billion, a P/E ratio of 43.81, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. The firm has a 50-day simple moving average of $22.94 and a two-hundred day simple moving average of $20.99.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the prior year, the firm posted $0.31 EPS. Kenvue’s quarterly revenue was down .4% compared to the same quarter last year. As a group, equities analysts predict that Kenvue will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

Institutional Trading of Kenvue

Large investors have recently added to or reduced their stakes in the stock. Riverview Trust Co acquired a new stake in shares of Kenvue during the 3rd quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue during the third quarter worth $35,000. Deseret Mutual Benefit Administrators raised its position in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares during the period. Studio Investment Management LLC raised its position in Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares during the period. Finally, Brooklyn Investment Group acquired a new position in shares of Kenvue in the 3rd quarter valued at $71,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.